The (68)Ga/(177)Lu-theragnostic concept in PSMA-targeting of metastatic castration–resistant prostate cancer: impact of post-therapeutic whole-body scintigraphy in the follow-up

por Maffey-Steffan, Johanna, Scarpa, Lorenza, Svirydenka, Anna, Nilica, Bernhard, Mair, Christian, Buxbaum, Sabine, Bektic, Jasmin, von Guggenberg, Elisabeth, Uprimny, Christian, Horninger, Wolfgang, Virgolini, Irene
Publicado 2019

A Randomized, Factorial Phase II Study to Determine the Optimal Dosing Regimen for (68)Ga-Satoreotide Trizoxetan as an Imaging Agent in Patients with Gastroenteropancreatic Neuroen...

por Virgolini, Irene, Bahri, Shadfar, Kjaer, Andreas, Grønbæk, Henning, Iversen, Peter, Carlsen, Esben A., Loft, Mathias, Knigge, Ulrich, Maffey-Steffan, Johanna, Powell, Christine, Miller, Colin G., Rohban, Thomas, McEwan, Sandy, Czernin, Johannes
Publicado 2022

Prior therapies as prognostic factors of overall survival in metastatic castration-resistant prostate cancer patients treated with [(177)Lu]Lu-PSMA-617. A WARMTH multicenter study...

por Ahmadzadehfar, Hojjat, Rahbar, Kambiz, Baum, Richard P., Seifert, Robert, Kessel, Katharina, Bögemann, Martin, Kulkarni, Harshad R, Zhang, Jingjing, Gerke, Carolin, Fimmers, Rolf, Kratochwil, Clemens, Rathke, Hendrik, Ilhan, Harun, Maffey-Steffan, Johanna, Sathekge, Mike, Kabasakal, Levent, Garcia-Perez, Francisco Osvaldo, Kairemo, Kalevi, Maharaj, Masha, Paez, Diana, Virgolini, Irene
Publicado 2020